Evidence map›Paper›PMID 27924072›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2016

P53 and Murine Double Mimute 2 (MDM2) Expression Changes and Significance in Different Types of Endometrial Lesions.

Zhongyong Jiang, Wanqing Xu, Gang Dan, Yuan Liu, Jie Xiong

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zhongyong JiangDepartment of Clinical Laboratory, Chengdu Military General Hospital, Chengdu Military District, Chengdu, Sichuan, China (mainland).
Wanqing XuDepartment of Clinical Laboratory, Chengdu Military General Hospital, Chengdu Military District, Chengdu, Sichuan, China (mainland).
Gang DanDepartment of Clinical Laboratory, Chengdu Military General Hospital, Chengdu Military District, Chengdu, Sichuan, China (mainland).
Yuan LiuDepartment of Clinical Laboratory, Chengdu Military General Hospital, Chengdu Military District, Chengdu, Sichuan, China (mainland).
Jie XiongDepartment of Clinical Laboratory, Chengdu Military General Hospital, Chengdu Military District, Chengdu, Sichuan, China (mainland).
Chengdu Military General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Endometrial lesions are common in obstetrics and gynecology, including endometrial polyps, uterine adenomyosis, and malignant endometrial adenocarcinoma. Endometrial lesions seriously affect women's health, fertility, quality of life, and life safety. As a pro-apoptosis gene, p53 is considered to be closely related with human tumors. Murine double mimute 2 (MDM2) is an oncogene that can promote tumor occurrence and development. P53 and MDM2 expression and significance in different types of endometrial lesions have not been fully elucidated. MATERIAL AND METHODS Normal endometrium, endometrial polyps, uterine adenomyosis, and endometrial adenocarcinoma tissue samples were collected. Real-time PCR was used to detect p53 and MDM2 mRNA expression. Immunohistochemical staining and Western blot analysis were applied to test p53 and MDM2 protein expression. Their correlation with clinical staging of endometrial adenocarcinoma was analyzed. RESULTS P53 and MDM2 mRNA and protein expression were significantly elevated in the endometrial polyps group and the endometrial adenocarcinoma group compared with the normal control group (P<0.05). Their levels increased more obviously in endometrial adenocarcinoma compared with endometrial polyps (P<0.05). P53 and MDM2 mRNA and protein expression were slightly enhanced in uterine adenomyosis compared with normal controls, but this difference lacked statistical significance (P>0.05). P53 and MDM2 mRNA and protein level showed a positive correlation. Significantly higher expression of p53 or MDM2 was observed in patients with stage III compared to those in patients with stage II. Higher expression was also observed in patients with stage II than in patients with stage I. CONCLUSIONS P53 and MDM2 mRNA and protein were elevated in endometrial polyps and endometrial adenocarcinoma and their expressions were correlated with clinical staging of endometrial adenocarcinoma. They can promote cancer occurrence and development, and can be treated to assist diagnosis and provide a reference for treatment.

Indexed as

AdenocarcinomaAdenomyosisAdultAgedDiagnosis, DifferentialEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm StagingPolypsProto-Oncogene Proteins c-mdm2Quality of LifeRNA, MessengerTumor Suppressor Protein p53MDM2 protein, humanProto-Oncogene Proteins c-mdm2RNA, MessengerTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID27924072
PMCPMC5158131
OpenAlexW2559954938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.